Snapshot from Jul 07, 2026 at 01:18 UTC. For live data and tracking: View Live
Entities / United States / Mapp Biopharmaceutical

United States & Mapp Biopharmaceutical

1 shared events · Importance 3 · Last updated Jul 04, 2026

Importance
3
Shared Events
1
Actions
0
Sentiment
0
Live sentiment trends, interaction importance charts, and action volume tracking available on the Ergen Dashboard
Shared Events (1)
55
Tech
Ebola Treatment Trial Begins DRC
United States: The United States government has funded research for MBP134 and owns doses of the drug, contributing to the clinical trial efforts.
Mapp Biopharmaceutical: Mapp Biopharmaceutical developed MBP134, an experimental monoclonal antibody treatment being tested in the Ebola clinical trial. The United States government has funded research for this drug.
Apr 20, 2026 · 67 articles
NEWSDESK
Explore this relationship live

Track how United States and Mapp Biopharmaceutical interact across events, view sentiment trends, and discover connected entities.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.